Experienced in Non-Hodgkin Lymphoma

Tuphan K. Dolai-Kanti

Kolkata, WB, IN 
Clinical Trials:Currently Recruiting for 1 Trial
Experienced in Non-Hodgkin Lymphoma
Kolkata, WB, IN 
OverviewLocationsClinical Research

Overview

Tuphan Dolai-Kanti practices in Kolkata, India. Dolai-Kanti is rated as an Experienced expert by MediFind in the treatment of Non-Hodgkin Lymphoma. Their top areas of expertise are Hemoglobin E Disease, Beta Thalassemia, Anemia, and Thalassemia.

Their clinical research consists of co-authoring 71 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 6 articles and participated in 1 clinical trial in the study of Non-Hodgkin Lymphoma.

Locations

Kolkata, WB, India
Other Locations
New Delhi, DL, India
Ratan, JK, India

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Phase 2b Open-label Study of Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
A Phase 2b Open-label Study of Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Enrollment Status: Recruiting
Publish Date: October 01, 2025
Intervention Type: Drug
Study Drug: Selinexor
Study Phase: Phase 2
A Phase 3 Randomized, Controlled, Open-label Study of Selinexor, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)
A Phase 3 Randomized, Controlled, Open-label Study of Selinexor, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)
Enrollment Status: Completed
Publish Date: August 21, 2024
Intervention Type: Drug
Study Drugs: Selinexor, Bortezomib, Dexamethasone
Study Phase: Phase 3
A Prospective, Multicenter, Open-label, Single-arm Study to Evaluate the Efficacy and Safety of Human Plasma-derived Fibrinogen Concentrate (FIB Grifols) in Subjects With Congenital Afibrinogenaemia and Severe Hypofibrinogenemia Requiring Either On-demand Treatment for Acute Bleeding or Surgical Prophylaxis
A Prospective, Multicenter, Open-label, Single-arm Study to Evaluate the Efficacy and Safety of Human Plasma-derived Fibrinogen Concentrate (FIB Grifols) in Subjects With Congenital Afibrinogenaemia and Severe Hypofibrinogenemia Requiring Either On-demand Treatment for Acute Bleeding or Surgical Prophylaxis
Enrollment Status: Withdrawn
Publish Date: October 23, 2023
Intervention Type: Biological
Study Phase: Phase 3
View 2 Less Clinical Trial

69 Total Publications

Unmet Needs in Hemophilia: A Narrative Review.
Unmet Needs in Hemophilia: A Narrative Review.
Journal: The Journal of the Association of Physicians of India
Published: August 21, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dolai-Kanti's expertise for a condition
ConditionClose
      View All 8 Advanced Conditions
      View All 19 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile